Juan M. Dominguez-Alonso

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Co-mutation signatures are age-dependent and impact the prognosis in NPM1-mutated acute myeloid leukemia: a PETHEMA multicenter study.

Co-mutation signatures are age-dependent and impact the prognosis in NPM1-mutated acute myeloid leukemia: a PETHEMA multicenter study.

Journal: Haematologica

Published: July 07, 2026

Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study.

Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study.

Journal: Blood

Published: February 05, 2026

Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera.

Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera.

Journal: Blood cancer journal

Published: January 30, 2026

Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real-world analysis from the PETHEMA registry.

Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real-world analysis from the PETHEMA registry.

Journal: Cancer

Published: November 03, 2025

The effects of the PHF6 gene mutation on myeloid neoplasms. A single-center cohort underpinned by a systematic review of literature.

The effects of the PHF6 gene mutation on myeloid neoplasms. A single-center cohort underpinned by a systematic review of literature.

Journal: Annals of hematology

Published: October 08, 2025

A novel GATA1 variant linking germline and somatic myelodysplastic syndrome in two patients.

A novel GATA1 variant linking germline and somatic myelodysplastic syndrome in two patients.

Journal: Haematologica

Published: September 05, 2025

Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain.

Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain.

Journal: Annals of hematology

Published: April 09, 2025

Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B‑8800 in lower-risk myelodysplastic syndrome.

Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B‑8800 in lower-risk myelodysplastic syndrome.

Journal: Leukemia research

Published: January 21, 2025

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA Study.

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA Study.

Journal: Cancers

Published: January 13, 2025

Therapeutics of acute myeloid leukemia with central nervous system involvement.

Therapeutics of acute myeloid leukemia with central nervous system involvement.

Journal: Clinical hematology international

Published: November 04, 2024

Flow Cytometry Analysis of Mesenchymal Stem Cells: A Predictive Biomarker for Leukemia Transformation in Myelodysplastic Syndrome.

Flow Cytometry Analysis of Mesenchymal Stem Cells: A Predictive Biomarker for Leukemia Transformation in Myelodysplastic Syndrome.

Journal: EJHaem

Published: October 23, 2024

Prognostic relevance of variant allele frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registry.

Prognostic relevance of variant allele frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registry.

Journal: Haematologica

Published: July 21, 2024

Showing 1-12 of 48

Last Updated: 09/26/2026